Day 2 Program

Poster Spotlight 2: CNS

Day 2: December 9, 2026

7:00 AM–8:30 AM CST

221 ABC

Session Details

Moderator

Andrew Brenner, University of Texas Health Science Center at San Antonio, San Antonio, TX

PS2-1

Exploratory Analysis of CNS-First Relapse in Early Breast Cancer: A Pooled Analysis of the TRIO and GEICAM Trials

Gonzalo D Spera, Translational Research in Oncology, Montevideo, Uruguay

PS2-2

Isolated Central Nervous System (CNS) Recurrence in Metastatic Breast Cancer (mBC): Clinical Features, Treatment Patterns and Outcomes

Angelika M. Starzer, Dana-Farber Cancer Institute, Boston, MA

PS2-3

Surveillance Brain MRIs in Stage IV Breast Cancer: Long Term Results and Biomarker Analysis from a Phase II Trial

Kamran Ahmed, Moffitt Cancer Center, Tampa, FL

PS2-4

Patterns of distant and central nervous system (CNS) recurrences by residual disease (RD) in patients (pts) with triple-negative breast cancer (TNBC) treated with neoadjuvant chemoimmunotherapy: a cohort study

Giacomo De Micheli, European Institute of Oncology, IRCCS, Milan, Italy

PS2-5

Spatial Distribution of Breast Cancer Brain Metastases Predicts Overall Survival Independent of Subtype

Daniel Grange, Memorial Sloan Kettering Cancer Center, New York, NY

PS2-6

Getting Ahead of CNS Metastases — Risk, Patterns of Relapse, and Early Detection

Katarzyna Jerzak

PS2-7

Trastuzumab deruxtecan in patients with HER2-low breast cancer and active brain metastases: the TUXEDO-4 phase II trial

Maximilian Marhold, Medical University of Vienna, Vienna, Austria

PS2-8

Datopotamab-deruxtecan (Dato-DXd) in active brain metastases (BM) from triple-negative breast cancer (TNBC): Primary outcome analysis from the TUXEDO-2 trial

Rupert Bartsch, Medical University of Vienna, Vienna, Austria

PS2-9

Alert-based ePRO monitoring improves quality of life and survival in metastatic breast cancer patients with brain metastases: results from the PRO B trial

Elena Laakmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

PS2-12

Treatment and Outcomes in Established CNS Metastases

Nancy U. Lin, Dana-Farber Cancer Institute, Boston, MA